|Bid||45.25 x 1100|
|Ask||45.33 x 800|
|Day's Range||44.73 - 46.60|
|52 Week Range||14.56 - 57.20|
|Beta (5Y Monthly)||3.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?